成人脓毒症患者较低与较高液体量:更新系统评价、Meta分析与试验序贯分析
该更新系统评价与Meta分析纳入13项随机临床试验(N=4,006),比较成人脓毒症患者较低与较高静脉液体量,其中4项试验(n=3,385)为本更新新增。8项低偏倚风险试验的全因死亡率Meta分析显示RR 0.99(97%CI 0.89-1.10;中等确定性证据);6项预设严重不良事件定义的试验显示RR 0.95(97%CI 0.83-1.07;低确定性证据)。健康相关生活质量无试验报告。作者认为较低液体量可能对全因死亡率与严重不良事件均无实质差异,但估计不精确,不能排除潜在获益或危害。
要点
- 8项低偏倚风险试验的全因死亡率:较低vs较高液体量RR 0.99(97%CI 0.89-1.10;中等确定性证据)。
- 6项预设严重不良事件定义的试验:RR 0.95(97%CI 0.83-1.07;低确定性证据),无显著差异。
- 健康相关生活质量无试验报告。
- 作者认为较低液体量可能对全因死亡率与严重不良事件均无实质差异,但估计不精确,不能排除潜在获益或危害。
- 共纳入13项随机临床试验(N=4,006),本更新新增4项(n=3,385)。
适用人群与场景
- 成人脓毒症患者(随机临床试验纳入人群)。
研究设计与关键结果
- 研究类型:更新系统评价、Meta分析与试验序贯分析,纳入13项随机临床试验(N=4,006),本更新新增4项试验(n=3,385)。
- 共同主要结局:全因死亡率、严重不良事件、健康相关生活质量。
- 全因死亡率:8项低偏倚风险试验,较低vs较高液体量RR 0.99(97%CI 0.89-1.10;中等确定性证据)。
- 严重不良事件:6项预设严重不良事件定义的试验,RR 0.95(97%CI 0.83-1.07;低确定性证据)。
- 健康相关生活质量:无试验报告。
证据类型、等级与局限
- 证据类型:随机临床试验的系统评价、Meta分析与试验序贯分析;采用Cochrane手册推荐与GRADE方法。
- 全因死亡率:中等确定性证据;严重不良事件:低确定性证据。
- 局限:作者指出解释受估计不精确限制,不能排除潜在获益或危害。
对床旁实践的改变
- 作者认为,成人脓毒症中较低静脉液体量相比较高液体量可能对全因死亡率与严重不良事件均无实质差异,但估计不精确,不能排除潜在获益或危害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: IV fluids are recommended for adults with sepsis. However, the optimal strategy for IV fluid management in sepsis is unknown, and clinical equipoise exists.
RESEARCH QUESTION: Do lower vs higher fluid volumes improve patient-important outcomes in adult patients with sepsis?
STUDY DESIGN AND METHODS: We updated a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials assessing lower vs higher IV fluid volumes in adult patients with sepsis. The coprimary outcomes were all-cause mortality, serious adverse events, and health-related quality of life. We followed the recommendations from the Cochrane Handbook and used the Grading of Recommendations Assessment, Development and Evaluation approach. Primary conclusions were based on trials with low risk of bias if available.
RESULTS: We included 13 trials (N = 4,006) with four trials (n = 3,385) added to this update. The meta-analysis of all-cause mortality in eight trials with low risk of bias showed a relative risk of 0.99 (97% CI, 0.89-1.10; moderate certainty evidence). Six trials with predefined definitions of serious adverse events showed a relative risk of 0.95 (97% CI, 0.83-1.07; low certainty evidence). Health-related quality of life was not reported.
INTERPRETATION: Among adult patients with sepsis, lower IV fluid volumes probably result in little to no difference in all-cause mortality compared with higher IV fluid volumes, but the interpretation is limited by imprecision in the estimate, which does not exclude potential benefit or harm. Similarly, the evidence suggests lower IV fluid volumes result in little to no difference in serious adverse events. No trials reported on health-related quality of life.
TRIAL REGISTRATION: PROSPERO; No.: CRD42022312572; URL: https://www.crd.york.ac.uk/prospero/.
参考来源
- Sivapalan P, Ellekjaer KL, Jessen MK, et al. Lower vs Higher Fluid Volumes in Adult Patients With Sepsis: An Updated Systematic Review With Meta-Analysis and Trial Sequential Analysis. Chest. 2023. PMID: 37142091. doi:10.1016/j.chest.2023.04.036
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。